Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclarion, Inc. stock logo
ACON
Aclarion
$6.88
+2.7%
$9.16
$6.20
$3,499.51
$4.00M1.1356,749 shs26,620 shs
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$1.79
+7.8%
$1.75
$1.03
$2.55
$13.43M77.73540,188 shs36,494 shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$1.89
+11.8%
$1.98
$1.32
$7.66
$9.77M2.45207,936 shs536,774 shs
Ontrak, Inc. stock logo
OTRK
Ontrak
$1.59
+1.3%
$1.53
$1.27
$5.53
$6.71M2.3450,709 shs33,535 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclarion, Inc. stock logo
ACON
Aclarion
+2.69%-1.01%-8.39%-92.28%-99.76%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
+7.83%+14.38%+4.68%-6.28%+38.76%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
+11.83%+19.62%+4.42%-57.34%-97.96%
Ontrak, Inc. stock logo
OTRK
Ontrak
+1.27%+1.27%+7.43%+6.71%-60.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclarion, Inc. stock logo
ACON
Aclarion
1.0224 of 5 stars
3.32.00.00.00.00.00.6
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.3183 of 5 stars
3.55.00.00.00.73.31.3
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.3629 of 5 stars
0.02.00.00.02.31.70.0
Ontrak, Inc. stock logo
OTRK
Ontrak
2.5113 of 5 stars
3.55.00.00.01.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclarion, Inc. stock logo
ACON
Aclarion
2.50
Moderate Buy$11,758.50170,808.43% Upside
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
3.00
Buy$18.00905.59% Upside
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00
N/AN/AN/A
Ontrak, Inc. stock logo
OTRK
Ontrak
3.00
Buy$45.002,730.19% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclarion, Inc. stock logo
ACON
Aclarion
$54.60K73.33N/AN/A($125.39) per share-0.05
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
$391K34.36N/AN/A$2.45 per share0.73
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$511.08K19.12N/AN/A$0.54 per share3.50
Ontrak, Inc. stock logo
OTRK
Ontrak
$10.18M0.66N/AN/A$5.56 per share0.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclarion, Inc. stock logo
ACON
Aclarion
-$4.91MN/A0.00N/AN/A-12,845.05%-422.87%-201.15%N/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$14.41M-$1.47N/AN/AN/A-2,697.08%-98.49%-75.23%8/12/2025 (Estimated)
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$9.21M-$4.64N/AN/A-1,237.00%-138.00%-118.88%N/A
Ontrak, Inc. stock logo
OTRK
Ontrak
-$27.92M-$15.81N/AN/AN/A-237.77%-171.34%-113.42%8/6/2025 (Estimated)

Latest ACON, BRTX, MGRX, and OTRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Ontrak, Inc. stock logo
OTRK
Ontrak
-$1.24-$1.65-$0.41-$1.65N/A$2.02 million
5/15/2025Q1 2025
Aclarion, Inc. stock logo
ACON
Aclarion
-$1,447.20-$9.32+$1,437.88-$9.32$0.02 million$0.02 million
5/15/2025Q1 2025
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.29N/A-$1.29N/A$0.11 million
5/14/2025Q1 2025
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million
4/14/2025Q4 2024
Ontrak, Inc. stock logo
OTRK
Ontrak
-$1.35-$9.54-$8.19-$9.54$3.08 million$3.08 million
3/27/2025Q4 2024
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million
3/20/2025Q4 2024
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.01N/A-$1.01N/A$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclarion, Inc. stock logo
ACON
Aclarion
N/AN/AN/AN/AN/A
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
Ontrak, Inc. stock logo
OTRK
Ontrak
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclarion, Inc. stock logo
ACON
Aclarion
N/A
2.80
2.80
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
N/A
2.95
2.95
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
0.07
0.07
Ontrak, Inc. stock logo
OTRK
Ontrak
0.19
1.17
1.17

Institutional Ownership

CompanyInstitutional Ownership
Aclarion, Inc. stock logo
ACON
Aclarion
7.52%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
69.38%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%
Ontrak, Inc. stock logo
OTRK
Ontrak
12.95%

Insider Ownership

CompanyInsider Ownership
Aclarion, Inc. stock logo
ACON
Aclarion
0.77%
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
25.50%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
16.00%
Ontrak, Inc. stock logo
OTRK
Ontrak
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclarion, Inc. stock logo
ACON
Aclarion
7582,000505,000Not Optionable
BioRestorative Therapies, Inc. stock logo
BRTX
BioRestorative Therapies
77.51 million5.16 millionNot Optionable
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
35.17 million1.51 millionNot Optionable
Ontrak, Inc. stock logo
OTRK
Ontrak
2504.22 million4.14 millionNo Data

Recent News About These Companies

Ontrak (NASDAQ:OTRK) Shares Up 1.9% - Here's Why
Ontrak reports Q4 EPS ($9.29) vs. ($4.02) last year
Ontrak secures Medicaid provider designation in two new states
ONTRAK INC. DL -,0001 (HY10.DU)
Ontrak Inc (HY10.MU)
Ontrak Inc. (HY10.SG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclarion stock logo

Aclarion NASDAQ:ACON

$6.88 +0.18 (+2.69%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.88 +0.00 (+0.07%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

BioRestorative Therapies stock logo

BioRestorative Therapies NASDAQ:BRTX

$1.79 +0.13 (+7.83%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.74 -0.05 (-3.07%)
As of 05/27/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Mangoceuticals stock logo

Mangoceuticals NASDAQ:MGRX

$1.89 +0.20 (+11.83%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.89 0.00 (0.00%)
As of 05:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Ontrak stock logo

Ontrak NASDAQ:OTRK

$1.59 +0.02 (+1.27%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.58 -0.01 (-0.31%)
As of 05:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. Ontrak, Inc. was incorporated in 2003 and is headquartered in Miami, Florida.